Survival outcomes in patients who underwent CAR T-cell therapy according to receipt of BT. Kaplan-Meier estimates of PFS (A) and OS (B) according to type of BT (no bridging, ST, RT, or CMT with RT concurrently with ST). The numbers of patients at risk in 5-month intervals are indicated.